Skip to Content


Treatment for Contraception

Akzo Nobel’s Contraceptive Implanon Receives “approvable” Status from the FDA

ARNHEM, The Netherlands, November 3, 2004 – Akzo Nobel’s human pharmaceutical business Organon announced today that the U.S. Food and Drug Administration (FDA) has granted the contraceptive Implanon (etonogestrel sub-dermal implant) “approvable” status.

Implanon is a small, flexible rod, about the size of a matchstick, that contains etonogestrel, a progestin. Once inserted under the skin, the rod continually releases a low dose of etonogestral into the bloodstream, which provides contraceptive protection. Implanon is one of the innovative contraceptive products developed by Organon in recent years.

“Organon recognizes the market need for diversity in the contraceptive marketplace and Implanon will provide women in the U.S. with a new method of contraception,” said Toon Wilderbeek, President of Organon International and Member of Akzo Nobel’s Board of Management.

For more information, please visit

Posted: November 2004

Related Articles

Implanon (etonogestrel) FDA Approval History